T cell-based immunotherapies, such as checkpoint inhibitors and cell therapies, are now effective options against a variety of advanced cancers. However, they don’t work in all cases, largely because of the tumor microenvironment, which can keep T cells out, exhaust them, and suppress their activity. With a better understanding of T cell signaling pathways, we might be able to better design treatments to optimize their cancer-fighting capabilities via immunotherapy.
To that end, Dr. Zeng aims to explore the microclusters that form on the surfaces of T cells, and how these complex signaling hubs promote T cell activation. This might reveal new insights that can be used to guide how we design T cell therapies against cancer.
Projects and Grants
Control of Lipid Signaling by Phase Separation in T Cell Activation
Yale University | All Cancers | 2021 | Xiaolei Su, Ph.D.
Let's spread the word about Immunotherapy! Click to share this page with your community.